Last 12 months
Inside the activity.
6 purchase rows · 67 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 28 |
| Dec 2025 | 5 | 22 |
| Jan 2026 | 0 | 9 |
| Feb 2026 | 1 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 6 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC |
Uihlein Richard EDirector · 10% owner
|
Exercise / conversionLine of Credit Convertible Notes · Derivative | Not disclosed | $10,331,275.00 Strike: $4.05 | $10,331,275.00 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · derivative · entry 5 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 0 Underlying: Common Stock · 2,550,932 shares Expires 2027-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · reported_value: Consists of $10,000,000 of principal and $331,275 of accrued interest. F2 · price: Consists of $10,000,000 of principal and $331,275 of accrued interest. F3 · derivative.exercise_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. F3 · derivative.expiration_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC |
Uihlein Richard EDirector · 10% owner
|
Exercise / conversionLine of Credit Convertible Notes · Derivative | Not disclosed | $95,475,705.00 Strike: $3.00 | $95,475,705.00 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · derivative · entry 4 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 0 Underlying: Common Stock · 31,825,235 shares Expires 2027-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · reported_value: Consists of $91,000,000 in principal and $14,475,705 in accrued interest. F1 · price: Consists of $91,000,000 in principal and $14,475,705 in accrued interest. F3 · derivative.exercise_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. F3 · derivative.expiration_date: The Line of Credit Convertible Notes are exercisable upon issuance when the issuer draws on the Line of Credit. Notes were issued on December 19, 2022; March 31, 2023; June 30, 2023; December 29, 2023; March 29, 2024; June 28, 2024; September30, 2024; April 30, 2025; June 30, 2025 and December 31, 2025. There was no expiration date; however, the maturity date of all Line of Credit Convertible Notes was June 30, 2027. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC |
Uihlein Richard EDirector · 10% owner
|
Exercise / conversionCommon Stock | 2,550,932 | $4.05 | $10,331,274.60 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · nonDerivative · entry 2 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 44,713,843 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 11:52 UTC |
Uihlein Richard EDirector · 10% owner
|
Exercise / conversionCommon Stock | 31,825,235 | $3.00 | $95,475,705.00 |
DisclosureSEC source: 0001133416-26-000065 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Richard E. Uihlein Stock Trust Disclosed balance after: 42,162,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 21:39 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 16,250 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000063 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 16,250 shares Expires 2036-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 21:39 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 16,250 | $5.13 | $83,284.50 |
DisclosureSEC source: 0001133416-26-000063 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 21:39 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionCommon Stock | 16,250 | $3.04 | $49,400.00 |
DisclosureSEC source: 0001133416-26-000063 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:24 UTC |
Shlevin Harold H.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 22,268 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · derivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 22,268 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3 · derivative.exercise_date: The options vested 100% on December 31, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:24 UTC |
Shlevin Harold H.Director
|
SaleCommon Stock | 22,268 | $5.04 | $112,230.72 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F4 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:24 UTC |
Shlevin Harold H.Director
|
Exercise / conversionCommon Stock | 22,268 | $1.23 | $27,389.64 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 47,467 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · derivative · entry 9 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,467 shares Expires 2034-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F4 · derivative.exercise_date: The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 47,467 | $5.04 | $239,233.68 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 6 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F5 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionCommon Stock | 47,467 | $2.50 | $118,667.50 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 5 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:24 UTC |
Shlevin Harold H.Director
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,732 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · derivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,268 Underlying: Common Stock · 7,732 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3 · derivative.exercise_date: The options vested 100% on December 31, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:24 UTC |
Shlevin Harold H.Director
|
SaleCommon Stock | 7,732 | $5.00 | $38,660.00 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:24 UTC |
Shlevin Harold H.Director
|
Exercise / conversionCommon Stock | 7,732 | $1.23 | $9,510.36 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,533 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · derivative · entry 8 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,467 Underlying: Common Stock · 2,533 shares Expires 2034-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F4 · derivative.exercise_date: The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 2,037 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · derivative · entry 7 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 2,037 shares Expires 2034-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 2,533 | $5.00 | $12,665.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 4 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionCommon Stock | 2,533 | $2.50 | $6,332.50 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 2,037 | $5.00 | $10,185.00 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:23 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionCommon Stock | 2,037 | $2.20 | $4,481.40 |
DisclosureSEC source: 0001133416-26-000059 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:06 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 7,557 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000057 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 7,557 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vested as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:06 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 7,557 | $3.14 | $23,728.98 |
DisclosureSEC source: 0001133416-26-000057 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $3.10 to $3.17. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:06 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionCommon Stock | 7,557 | $1.23 | $9,295.11 |
DisclosureSEC source: 0001133416-26-000057 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| May 26, 2026 Filed May 28, 2026 13:13 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionStock option (right to buy) · Derivative | 568 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000055 · form4.xml · derivative · entry 3 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,057 Underlying: Common Stock · 568 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F3 · derivative.exercise_date: The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026. Read SEC document |
| May 26, 2026 Filed May 28, 2026 13:13 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 568 | $3.10 | $1,761.03 |
DisclosureSEC source: 0001133416-26-000055 · form4.xml · nonDerivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 F2 · price: The shares were sold in multiple transactions at prices ranging from $3.00 to $3.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 13:13 UTC |
Jamil KhurramChief Medical Officer
|
Exercise / conversionCommon Stock | 568 | $1.23 | $698.64 |
DisclosureSEC source: 0001133416-26-000055 · form4.xml · nonDerivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 Read SEC document |
| March 12, 2026 Filed Mar 17, 2026 13:46 UTC |
Brem HenryDirector
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001133416-26-000053 · form4.xml · derivative · entry 1 Brem Henry · CIK 0001387877 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-03-12 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 21:25 UTC |
ELDRED KARYDirector
|
PurchaseCommon Stock | 300 | $2.70 | $810.00 |
DisclosureSEC source: 0001133416-26-000048 · form4.xml · nonDerivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,682 Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 22:03 UTC |
CARSON BENJAMIN SRDirector
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000043 · form4.xml · derivative · entry 1 CARSON BENJAMIN SR · CIK 0000017940 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:50 UTC |
Zordani Richard A. Jr.Director
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000040 · form4.xml · derivative · entry 1 Zordani Richard A. Jr. · CIK 0001827180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:50 UTC |
Jamil KhurramChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000038 · form4.xml · derivative · entry 2 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:50 UTC |
Jamil KhurramChief Medical Officer
|
GrantStock option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000038 · form4.xml · derivative · entry 1 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-01-16 F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:49 UTC |
FREEMAN KEVIN DDirector
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000036 · form4.xml · derivative · entry 1 FREEMAN KEVIN D · CIK 0001522478 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:49 UTC |
ELDRED KARYDirector
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000034 · form4.xml · derivative · entry 1 ELDRED KARY · CIK 0001543425 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:48 UTC |
LEWIS JOELDirector · President and CEO
|
GrantRestricted Stock Unit · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000032 · form4.xml · derivative · entry 2 LEWIS JOEL · CIK 0001725595 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:48 UTC |
LEWIS JOELDirector · President and CEO
|
GrantStock option (right to buy) · Derivative | 84,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000032 · form4.xml · derivative · entry 1 LEWIS JOEL · CIK 0001725595 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 84,000 shares Expires 2036-01-16 F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:47 UTC |
CALLICUTT JACK WChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000030 · form4.xml · derivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:47 UTC |
CALLICUTT JACK WChief Financial Officer
|
GrantStock option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000030 · form4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-01-16 F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:46 UTC |
Shlevin Harold H.Director
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000028 · form4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:46 UTC |
OMENN GILBERT SDirector
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000026 · form4.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:45 UTC |
AMELIO GILBERT FDirector
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000024 · form4.xml · derivative · entry 1 AMELIO GILBERT F · CIK 0001183247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:44 UTC |
Schwartz Elissa J.Director
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000022 · form4.xml · derivative · entry 1 Schwartz Elissa J. · CIK 0001827177 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:44 UTC |
Uihlein Richard EDirector · 10% owner
|
GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000020 · form4.xml · derivative · entry 3 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:44 UTC |
Uihlein Richard EDirector · 10% owner
|
GrantCommon Stock | 13,158 | $3.04 | $40,000.32 |
DisclosureSEC source: 0001133416-26-000020 · form4.xml · nonDerivative · entry 1 Uihlein Richard E · CIK 0001694903 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,332,676 F3 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026. F3 · price: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 19:11 UTC Amendment |
LEWIS JOELDirector · President and CEO
|
GrantStock option (right to buy) · Derivative | 91,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000046 · form4a.xml · derivative · entry 1 LEWIS JOEL · CIK 0001725595 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2036-01-16 F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F3 · shares: The original Form 4 filed had an incorrect number of common stock options. This amendment presents the correct number of common stock options granted. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:54 UTC |
LEWIS JOELDirector · President and CEO
|
SaleCommon Stock | 37,698 | $3.58 | $134,853.29 |
DisclosureSEC source: 0001133416-26-000008 · form4.xml · nonDerivative · entry 4 LEWIS JOEL · CIK 0001725595 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 832,592 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F7 · price: The shares were sold in multiple transactions at prices ranging from $3.36 to $3.79. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:54 UTC |
CALLICUTT JACK WChief Financial Officer
|
SaleCommon Stock | 20,354 | $3.67 | $74,695.11 |
DisclosureSEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:53 UTC |
Jamil KhurramChief Medical Officer
|
SaleCommon Stock | 21,446 | $3.65 | $78,204.98 |
DisclosureSEC source: 0001133416-26-000004 · form4.xml · nonDerivative · entry 4 Jamil Khurram · CIK 0002032345 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $3.42. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.